Savara (SVRA) Raised to Hold at BidaskClub
BidaskClub upgraded shares of Savara (NASDAQ:SVRA) from a sell rating to a hold rating in a research note released on Saturday.
SVRA has been the topic of several other research reports. Ladenburg Thalmann Financial Services began coverage on Savara in a research report on Wednesday, January 3rd. They set a buy rating and a $35.00 price objective on the stock. Zacks Investment Research cut Savara from a buy rating to a hold rating in a research report on Thursday, November 23rd. ValuEngine cut Savara from a sell rating to a strong sell rating in a research report on Friday, December 1st. Canaccord Genuity increased their price objective on Savara from $18.00 to $25.00 and gave the stock a buy rating in a research report on Monday, October 30th. Finally, Roth Capital lowered their price objective on Savara from $40.00 to $32.00 and set a buy rating on the stock in a research report on Tuesday, October 31st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. Savara currently has an average rating of Buy and a consensus target price of $23.58.
Savara (NASDAQ SVRA) opened at $12.50 on Friday. The company has a current ratio of 9.15, a quick ratio of 9.15 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $356.86, a price-to-earnings ratio of -2.98 and a beta of -0.26. Savara has a 12-month low of $4.60 and a 12-month high of $17.19.
ILLEGAL ACTIVITY WARNING: “Savara (SVRA) Raised to Hold at BidaskClub” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://theolympiareport.com/2018/02/14/savara-svra-raised-to-hold-at-bidaskclub.html.
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.